DANCR exhibits different biological functions in different tumor types: KLF12 mediates the promotive effect of DANCR in HCC (218), while KLF9 is the ultimate target of the cancer-inhibiting effect of DANCR in multiple myeloma (219). Here, DANCR is linked to plasma cell myeloma.